Metastatic pituitary lesion
A. M. Lapshina,
E. A. Bazarova,
E. G. Przhialkovskaya,
P. M. Khandaeva,
V. N. Azizyan,
A. Yu. Grigoriev,
O. V. Ivashchenko,
N. V. Tarbaeva,
Zh. E. Belaya https://doi.org/10.14341/probl13395
Abstract
Metastatic lesion of pituitary is a rare condition and is diagnosed in 1.8–4% of cases. Monitoring and treatment of such patients is a complex task and requires increased attention from a multidisciplinary team of specialists. The authors represent three patients with metastatic pituitary lesion who underwent neurosurgical treatment at the National Research Center of the National Research Institute of Endocrinology with subsequent pathomorphological confirmation of the diagnosis. The primary tumors were breast cancer, lung carcinoid, and clear cell kidney cancer. Two patients had distant metastases other than the pituitary gland. The clinical manifestation consisted in the appearance of symptoms of panhypopituitarism, chiasmal syndrome and mass effect in all cases. The follow-up period after surgical treatment was 0.25–2.5 years. Progression of the underlying disease was noted in two patients. One of them carried out stereotactic radiosurgical treatment and stereotactic oriented irradiation. One patient has a stable condition.
About the Authors
A. M. Lapshina
Endocrinology Research Center
Russian Federation
Competing Interests:
Russian Federation
Anastasia M. Lapshina - MD, PhD.
11 Dm. Ulyanova street, 117292 Moscow
Competing Interests:
none
E. A. Bazarova
Endocrinology Research Center
Russian Federation
Competing Interests:
Russian Federation
Ekaterina V. Bazarova - MD.
11 Dm.Ulyanova street, 117292 Moscow
Competing Interests:
none
E. G. Przhialkovskaya
Endocrinology Research Center
Russian Federation
Competing Interests:
Russian Federation
Elena G. Przhialkovskaya - MD, PhD.
Moscow
Competing Interests:
none
P. M. Khandaeva
Endocrinology Research Center
Russian Federation
Competing Interests:
Russian Federation
Patimat M. Khandaeva - MD, PhD.
Moscow
Competing Interests:
none
V. N. Azizyan
Endocrinology Research Center
Russian Federation
Competing Interests:
Russian Federation
Vilen N. Azizyan - MD, PhD.
Moscow
Competing Interests:
none
A. Yu. Grigoriev
Endocrinology Research Center
Russian Federation
Competing Interests:
Russian Federation
Andrey Yu. Grigoriev - MD, PhD.
Moscow
Competing Interests:
none
O. V. Ivashchenko
Endocrinology Research Center
Russian Federation
Competing Interests:
Russian Federation
Oksana V. Ivashchenko - MD.
Moscow
Competing Interests:
none
N. V. Tarbaeva
Endocrinology Research Center
Russian Federation
Competing Interests:
Russian Federation
Natalya V. Tarbaeva - MD, PhD.
Moscow
Competing Interests:
none
Zh. E. Belaya
Endocrinology Research Center
Russian Federation
Competing Interests:
Russian Federation
Zhanna E. Belaya - MD, PhD.
Moscow
Competing Interests:
none
References
1. Mika H, Hiroshi T, Hirofumi H, Soichiro Y, Nagatomo Y. Pituitary metastases: current practice in Japan. J Neurosurg. 2015;123(21):998–1007 DOI: 10.3171/2014.12.JNS14870
2. Ng S, Fomekong F, Delabar V, Jacquesson T, Enachescu C, Raverot G, et al. Current status and treatment modalities in metastases to the pituitary: a systematic review. J Neurooncol [Internet]. 2020;146(2):219–27. Available from: https://doi.org/10.1007/s11060-020-03396-w
3. Shimon I. Metastatic Spread to the Pituitary. Neuroendocrinology. 2020;110(9–10):805–8 doi: https://doi.org/10.1159/000506810
4. Komninos J, Vlassopoulou V, Protopapa D, Korfias S, Kontogeorgos G, Sakas DE, et al. Tumors Metastatic to the Pituitary Gland: Case Report and Literature Review. J Clin Endocrinol Metab. 2004;89(2):574–80 doi: https://doi.org/10.1210/jc.2003-030395
5. Teears RJ, Silverman EM. Clinicopathologic review of 88 cases of carcinoma metastatic to the pituitary gland. Cancer. 1975;36(1):216–20 doi: https://doi.org/10.1002/1097-0142(197507)36:1<216::aid-cncr2820360123>3.0.co;2-e
6. Javanbakht A, D’Apuzzo M, Badie B, Salehian B. Pituitary metastasis: A rare condition. Endocr Connect. 2018;7(10):1049–57 doi: https://doi.org/10.1530/EC-18-0338
7. Shimon I. Metastatic Spread to the Pituitary. Neuroendocrinology. 2020;110(9–10):805–8
8. Kramer CK, Ferreira N, Silveiro SP, Gross JL, Dora JM, de Azevedo MJ. Pituitary gland metastasis from renal cell carcinoma presented as a non-functioning macroadenoma. Arq Bras Endocrinol Metabol. 2010;54(5):498–501 doi: https://doi.org/10.1590/s0004-27302010000500011
9. Leramo OB, Booth JD, Zinman B, Bergeron C, Sima AF, Morley TP. Hyperprolactinemia, hypopituitarism, and chiasmal compression due to carcinoma metastatic to the pituitary. Neurosurgery. 1981;8(4):477–80 doi: https://doi.org/10.1227/00006123-198104000-00015
10. Morita A, Meyer FB, Laws ER. Symptomatic pituitary metastases. J Neurosurg. 1998;89(1):69–73 doi: https://doi.org/10.3171/jns.1998.89.1.0069
11. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol [Internet]. 2022;33(1):6–26. Available from: https://doi.org/10.1007/s12022-022-09703-7
Supplementary files
|
|
1. Figure 1.1. Cystic-solid pituitary mass with supra- and laterosellar growth to the left, with compression of the chiasm, moderate deformation of the optic tracts and the third ventricle. | |
| Subject | ||
| Type | Research Instrument | |
View
(164KB)
|
Indexing metadata ▾ | |
|
|
2. Figure 1.2. Hematoxylin and eosin staining. | |
| Subject | ||
| Type | Research Instrument | |
View
(602KB)
|
Indexing metadata ▾ | |
|
|
3. Figure 1.3. Immunohistochemical study: no staining with antibodies to the transcription factor PIT1 in tumor cells when staining the adenohypophysis cells (black arrow). | |
| Subject | ||
| Type | Research Instrument | |
View
(337KB)
|
Indexing metadata ▾ | |
|
|
4. Figure 1.4. Immunohistochemical study: staining with antibodies to CK 7 in tumor cells. | |
| Subject | ||
| Type | Research Instrument | |
View
(419KB)
|
Indexing metadata ▾ | |
|
|
5. Figure 2.1. Hematoxylin and eosin staining. Glandular-like structures and tumor cells with signs of neuroendocrine differentiation. | |
| Subject | ||
| Type | Research Instrument | |
View
(716KB)
|
Indexing metadata ▾ | |
|
|
6. Figure 2.2. Immunohistochemical study: staining of tumor cell nuclei with antibodies to TTF-1. | |
| Subject | ||
| Type | Research Instrument | |
View
(653KB)
|
Indexing metadata ▾ | |
|
|
7. Figure 2.3. Immunohistochemical study: staining of tumor cell cytoplasm with antibodies to chromogranin A. | |
| Subject | ||
| Type | Research Instrument | |
View
(670KB)
|
Indexing metadata ▾ | |
|
|
8. Figure 3.1. CT scan of the brain. | |
| Subject | ||
| Type | Research Instrument | |
View
(256KB)
|
Indexing metadata ▾ | |
|
|
9. Figure 3.2. Hematoxylin and eosin staining. Clear cell renal cell carcinoma metastasis. | |
| Subject | ||
| Type | Research Instrument | |
View
(732KB)
|
Indexing metadata ▾ | |
|
|
10. Figure 3.3. Immunohistochemical study: staining of tumor cells with antibodies to CD10. | |
| Subject | ||
| Type | Research Instrument | |
View
(926KB)
|
Indexing metadata ▾ | |
Review
For citations:
Lapshina A.M., Bazarova E.A., Przhialkovskaya E.G., Khandaeva P.M., Azizyan V.N., Grigoriev A.Yu., Ivashchenko O.V., Tarbaeva N.V., Belaya Zh.E. Metastatic pituitary lesion. Problems of Endocrinology. 2024;70(5):46-53. (In Russ.) https://doi.org/10.14341/probl13395
Views:
678
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
